

 Early Warning System

EIB-20210619
EXEVIR (COVID-19) (IDFF)



Quick Facts

Countries	Belgium
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2022-04-01
Borrower	EXEVIR BIO BV
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 26.31 million
Project Cost (USD)	\$ 107.34 million



Project Description

According to the bank website, the Promoter is a Belgium-based clinical stage company that develops single-domain antibody-based therapies (VHH or nanobodies). The project supports the development of the company's lead product, XVR011 in COVID-19, including inter alia clinical and regulatory approvals in the EU and the US, scale-up of manufacturing operations and the research and development (R&D) activities for a sub-cutaneous formulation.

The EIB financing will support the R&D activities of the Promoter to further develop its lead candidate, XVR011, a COVID-19 therapeutic product derived from llama-derived nanobodies. The eligible investment plan incorporates R&D activities, including, inter alia, clinical trials, chemistry manufacturing activities, regulatory, and related expenses to finance the development of the product; whilst also progressing the development of an additional dosage form, a sub-cutaneous formulation, allowing for earlier intervention and thus addressing not only severe but also milder forms of the disease.



Investment Description

- European Investment Bank (EIB)



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	EXEVIR BIO BV	Client	-



Contact Information

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check:

http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at:

<http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>